NIKKEI 225
37,391.01 -688.69 (-1.81%) HANG SENG
16,385.87 +134.03 (+0.82%) CRUDE OIL
82.50 -0.23 (-0.28%) GOLD FUTURES
2,390.20 -7.80 (-0.33%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,807.04 +1,723.96 (+3.51%)
ProPhase Labs, Inc. (PRPH)
After hours:
| Previous close | 6.27 |
| Open | 6.32 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.33 - 6.32 |
| 52-week range | 4.05 - 9.94 |
| Volume | |
| Avg. volume | 30,837 |
| Market cap | 98.166M |
| Beta (5Y monthly) | -0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.98 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 24 May 2022 |
| 1y target est | 20.00 |
GlobeNewswireProPhase Labs Unveils Project ZenQ-AI
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company’s state-of-the-art AI platform which was
ZacksStrength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- GlobeNewswire
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
Garden City, NY, April 10, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs, commented, “The BE-Smart test is more than an advancement in medical technology; it is providing a criti
